Tirzepatide outperforms semaglutide in weight loss clinical trial
This article highlights the first head-to-head study comparing two popular injectable weight-loss medications, semaglutide (Wegovy) and tirzepatide (Zepbound). Conducted by Weill Cornell Medicine, the study revealed that tirzepatide outperforms semaglutide in terms of weight loss and waist circumference reduction. The study, which involved 751 adults with obesity, found that participants using tirzepatide experienced a significantly higher percentage of weight loss (20.2%) compared to those using semaglutide (13.7%). The research also explored the mechanisms behind these results, with tirzepatide’s dual action on GLP-1 and GIP receptors contributing to its superior effectiveness. The findings, presented at the European Congress on Obesity and published in The New England Journal of Medicine, have significant implications for the treatment of obesity.
